Eculizumab treatment in the salvage therapy of MOGAD: a case report.

Authors

Yuzhou Guo, Meiling Liu, Zhelin Zhang

Published in

Frontiers in immunology. Volume 17. Pages 1861880. Epub Jul 27, 2026.

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare inflammatory demyelinating disorder of the central nervous system. During the acute phase, management typically prioritizes high-dose methylprednisolone pulse therapy. When the patients show inadequate response, intravenous immunoglobulin (IVIG) or plasma exchange is recommended. We report the case of a 17-year-old male of Mongolian ethnicity who developed severe visual impairment following treatment for Epstein-Barr virus (EBV) meningitis, ultimately diagnosed with MOGAD. Following both methylprednisolone pulse therapy and IVIG, the patient exhibited a suboptimal response. However, his symptoms improved markedly after treatment with eculizumab. Subsequently, sequential therapy with ofatumumab was applied. At the six-month follow-up, the patient remained relapse-free and reported no adverse effects. This case suggests that eculizumab can serve as an effective salvage therapy for acute MOGAD refractory to conventional treatment. Ofatumumab may be a viable option for maintenance therapy during remission. These findings may provide valuable insights for future clinical research.

PMID:
42577385
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.